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Pharmacist interventionAbstract What is known and objective: There is little research on the impact of implementing and
monitoring antimicrobial policy in Saudi hospitals. The purpose of this study is to measure the
impact of the clinical pharmacist (CP) and infectious disease consultant (ID) interventions on the
use of three antimicrobials (caspofungin, imipenem, meropenem) in hospitalized patients in the
King Abdullah Medical City hospital.
Methods: The study was carried out in the King Abdullah Medical City, in Mekkah, Saudi Ara-
bia. The hospital is a tertiary center that provides CCU, CSICU, Cardiac, Hematology, ICU, Med-
ical, Neuroscience, Oncology, and specialized surgery services. The use of three antimicrobials
(caspofungin, imipenem, meropenem) was reviewed by the clinical pharmacist for four periods,
pre and post implementation of policy. Relevant data were collected in four periods. In the ﬁrst per-
iod, before policy implementation, data were collected retrospectively to be used as baseline status
reference, and in the three remaining periods that followed data were collected prospectively, and
compared to baseline data, to evaluate the role of clinical pharmacist and ID interventions in opti-
mizing antimicrobial therapy.
Results and discussion: Caspofungin duration of therapy was not affected signiﬁcantly by the
intervention. Statistically signiﬁcant reduction in antimicrobial therapy duration was observed in
imipenem (37%) and meropenem (37%) from baseline, which indicate a better control on antimi-
crobial use and reduction in antimicrobial resistance.
What is new and conclusion: The impact of the clinical pharmacist and ID interventions, in
reducing antimicrobial therapy duration using imipenem and meropenem, is clear from the result
presented above. However, lack of restriction and follow up in the antimicrobial policy in case
Impact of clinical pharmacist and ID intervention in rationalization of antimicrobial use 517of negative culture makes antimicrobial use uncontrollable in these cases. Establishing good and
accepted policy may help reduce consumption and total cost of therapy.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. What is known and objective
Little is known about the impact of implementing and moni-
toring an antimicrobial policy in Saudi hospitals. Most drug
related problems in hospitals are caused by anti-infectives
(Khdour et al., 2012). The rational of antimicrobial prescribing
is to use the safest and most effective antimicrobial agent
against relevant pathogens, with least impact on normal ﬂora
(Berild and Haug, 2008). Increased total consumption and
use of broad spectrum antibiotics are associated with increased
costs, medication errors and widespread antimicrobial resis-
tance (Berild and Haug, 2008; Scheetz et al., 2009). Dynamics
of resistance is a function of interacting variables (e.g., intro-
duction of resistance, infection control practices, and antimi-
crobial use) (Nijssen et al., 2006). Rules and guidelines alone
may not be enough to optimize antimicrobial prescribing prac-
tice (Charani et al., 2010). Need for intervention by clinical
pharmacist (CP) and infectious disease (ID) consultants in
managing the policy is well established. Clinical pharmacist
interventions eliminate (37.4%) of treatment problems related
to efﬁcacy and monitoring of medications (Aburuz et al.,
2013), promote efﬁcacy of therapy (Jarab et al., 2012), and en-
hance desired health outcomes (Jarab et al., 2011). Frequent
and prolonged use of broad-spectrum antimicrobial agents
promote emergence of resistance (Velickovic-Radovanovic
et al., 2012). Reserved antimicrobials should be used cau-
tiously as the last resort. From this reserve we selected one
antifungal (caspofungin), and two antibiotics (imipenem, and
meropenem). These are of interest because of cost (as in caspo-
fungin), emerging resistance, and being the last line of defense.
Our study aimed at assessing the role of the clinical pharmacist
and ID in optimizing antimicrobial therapy and preventing
misuse of antimicrobials.
Caspofungin is an echinocandin that inhibits the synthesis
of b(1,3)-D-glucan, an essential component of the cell wall of
susceptible Aspergillus and Candida species. It has been ap-
proved by the FDA for use in adults and pediatric patients
(P3 months of age) for empirical therapy for presumed fungal
infections in febrile, neutropenic patients; treatment of candi-
demia and the Candida infections (intra-abdominal abscesses,
peritonitis, and pleural space infections); treatment of esopha-
geal candidiasis; and treatment of invasive aspergillosis in pa-
tients who are refractory to or intolerant of other therapies
(e.g., amphotericin B, lipid formulations of amphotericin B,
itraconazole) (Merck Sharp et al., 2013).
Imipenem is a Thienamycin that inhibits cell-wall synthesis.
Cilastatin is a dehydropeptidase I inhibitor that prevents renal
metabolism of imipenem. Imipenem has been approved by the
FDA for the treatment of lower respiratory tract infections
(LRTI), skin and skin structure infections (SSSI), and intra-
abdominal and gynecologic infections caused by susceptible
strains of microorganisms (Merck Sharp et al., 2013).
Meropenem is a carbapenem that penetrates bacterial cell
walls to reach penicillin-binding-protein targets, thus inhibit-ing cell wall synthesis, resulting in cell death. The FDA has ap-
proved meropenem for the treatment of intra-abdominal
infections (complicated appendicitis and peritonitis), bacterial
meningitis, and complicated skin and skin structure infections
(cSSSI) caused by susceptible strains of microorganisms. It is
useful as presumptive therapy in the indicated condition prior
to identiﬁcation of causative organisms (AstraZeneca Pharma-
ceuticals LP, 2013).2. Methods
2.1. Study design
This is a retrospective follow up chart review study. The study
included 559 orders of antimicrobials in 357 patients in the
King Abdullah Medical City, in Mekkah, Saudi Arabia. The
hospital is a tertiary center that provides CCU, CSICU, Car-
diac, Hematology, ICU, Medical, Neuroscience, Oncology,
and specialized surgery services.
2.2. Measured outcome
Duration of antimicrobial therapy’s pre- and post-policy
implementation was measured, as well as, WHO-deﬁned daily
doses as per 100 bed days (DBD) as a marker for antimicrobial
consumption. DBD calculate treatment period in a standard-
ized fashion and allow inclusion of periods of shortage of
either 70 mg or 50 mg dosage-forms resulting in the replace-
ment of one dosage form for the other, and variation in doses
used (Chandwani et al., 2009; Kotapati et al., 2004). Same ap-
proach can verify the captured actual duration of therapy par-
allels WHO-standardized deﬁned daily doses (DDD) a patient
should receive on average to achieve cure.2.3. Inclusion and exclusion criteria
Our study included patients who received any of the three anti-
microbials in-hospital, during the study period, regardless of
their condition, age, sex, ward, or other variables. Patients
not on any of these medications were excluded from the study.
2.4. Study methodology
On a daily basis, the CP reviewed medical chart, lab tests and
culture reports and provided therapeutic interventions as
needed to the treating physicians regarding doses, interactions
and duration of antimicrobial therapy.
As a member of multidisciplinary team, the ID consultant
has the authority to change or stop any antimicrobial agent
and carries the responsibility of assuring proper antimicrobial
use in terms of agent selection, appropriate indication and
optimal duration of therapy.
Figure 1 Culture result for the three antimicrobials in the four
periods.
Table 1 Doses and World Health Organization deﬁned daily
doses for the three antimicrobials used in this study.
LDa MDb Duration (days) WHO-DDDc
Caspofungin 70 mg stat 50 mg OD 14 50 mg OD
Imipenem 500 mg BID 14 500 mg QID
Meropenem 500 mg TID 500 mg QID
a LD: loading dose.
b MD: maintenance dose.
c WHO-DDD: World Health Organization Deﬁne Daily Dose.
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meropenem) was reviewed by the clinical pharmacist for four
periods, one period pre and three periods post implementation
of the policy. The ﬁrst period (Period I) started on 1st of
March, 2011 and ended on 31st of August, 2011. The second
period (Period II) started on 1st of September, 2011 and ended
on 1st of December, 2011. The third period (Period III) started
on 2nd December, 2011 and ended on 31st March, 2012. The
fourth period (Period IV) started on 1st of April 2012 and
ended on 31st of August, 2012. Data were collected retrospec-
tively for the ﬁrst period to serve as the control group. The fol-
lowing data were collected: ﬁle number, ward, culture result,
quantity of consumption of antimicrobial, and duration of
therapy.
Drug distribution system in the hospital was explained to
enable proper interpretation of dates and calculation of time
periods and quantities identiﬁed in the study.
The patient identiﬁer included in the database is patient-
ﬁle number, and this identiﬁer was excluded from data pre-
sentation, and was only revealed for authorized pharmacy
personnel when debating an issue of a dose given to a patient
to clear the issue of appropriate dosing and enable identify-
ing the patient and prescriber. Information revealed were
never used to inﬂect penalty on identiﬁed people but rather
to help resolve clinical decision making errors and clear
information from human errors of entry into hospital infor-
mation-system.
The clinical pharmacist and ID interventions were based on
optimal duration of therapy based on Infectious Disease Soci-
ety of America (IDSA) updated-guidelines.
2.5. Statistical analysis
Data were subjected to statistical analysis comparing duration
of therapy, as well as DBD, among the four periods of the
study using Oneway-ANOVA test using STATA/IC 12.0 for
Windows. Microsoft Excel 2007 was used for data
management.
Results were compared between the four periods based on
culture-outcome as positive or negative.
3. Results and discussion
Duration of therapy analysis showed signiﬁcant reduction in
the average duration of use of imipenem and meropenem, in
the second and fourth periods of the study. Average Caspofun-
gin duration of therapy was (12.15, 7.70, 13.15, 10.97) days, for
Periods I, II, III, and IV respectively (F(3,93) = 0.84 ,
p= 0.4756), while average imipenem duration of therapy
was (10.52, 7.61, 8.86, 6.68) days, for the same periods respec-
tively (F(3,214) = 3.60, p= 0.0144). Meropenem duration of
therapy was (12.74, 7.38, 10.35, 7.99) days for the same periods
respectively (F(3,240) = 3.95, p= 0.0089). DBD analysis
showed similar results for the same periods and drugs.
Non-signiﬁcance of reduction of caspofungin DBD resulted
from the drug being used in culture-negative patients, as illus-
trated in Fig. 1, and failing to de-escalate therapy appropri-
ately (Levy et al., 2012). Off-label (Mukattash et al., 2011)
and prophylactic prescribing may impair control of caspofun-
gin. In these cases causative organisms were not identiﬁed and
drug therapy was empirical. The analysis was not expanded tothe number of microorganisms and number of infection sites
which could affect the result of the analysis (Jourdan et al.,
2003).
Results from implementing and fostering antimicrobial pol-
icy by clinical pharmacist and ID resulted in (37%) reduction
in consumption of imipenem and meropenem, which correlate
with reduction in antimicrobial resistance and associated costs.
Velickovic-Radovanovic et al. (2012) reported a similar result
(37.8%) (see Table 1).
Table 2 provides the analysis of antimicrobial use in all
wards and captures the prescribing habits in these wards. Once
wards with high consumption rate were identiﬁed a more fo-
cused approach was done to dictate the use of the antimicro-
bial under study to verify rational use of the drug and
minimize prolonged unnecessary use of the antimicrobial.
For example, the ICU was consuming the highest amount of
all three antimicrobials. The open structure of ICU ward al-
lows a higher consumption of antimicrobials with less control
to antibiotic prescription (Murunga et al., 2005). This pattern
is of concern as the ICU is associated with increased emergence
of resistance to treated organisms (Fish et al., 1995). In the ﬁrst
period, major sites of prolonged therapy were: medical ward
for all three antimicrobials, CCU for caspofungin, and the car-
diac ward for meropenem. In the second period, prolonged
therapy peaked in: specialized surgery consumption for caspo-
fungin and meropenem, hematology, ICU, and medical for
imipenem, and Oncology for meropenem. The third period
showed prolonged therapy in: ICU using caspofungin,
hematology, ICU, and medical ward using imipenem, and
CSICU using meropenem. In the last period prolonged
Table 2 Deﬁned daily doses per 100 bed days divided by the number of patients for caspofungin, imipenem, and meropenem during
the four periods of the study.
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Figure 2 Monthly patient number 2011–2012.
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nem, hematology with imipenem, and specialized surgery with
meropenem.
During Hajj time millions of pilgrims are received in Mek-
kah; this necessitates high patient turn over. Figs. 2 and 3 show
control of drug ordering habits during the period of peak
admission of patients, period II (September–December,
2011), the Hajj time.This drug utilization review (DUR) enabled auditing use of
caspofungin, imipenem, and meropenem in real time and was
conducted prospectively longitudinally. The interim reports
of this study provided surrogate markers for the result of ef-
forts of the ID and clinical pharmacist services in the whole
hospital vicinity.
This DUR included time of Hajj in Mekkah, during this
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Figure 3 Monthly unit/patient ratio 2011–2012.
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antimicrobial use.
The study served as a quality monitor of the hospital phar-
macist activity that pertains to clinical pharmacy service provi-
sion. This allowed correction of some potential error sources
and inspection of faulty entries to promote higher standards
of operation; thus some provision in medication safety
practice.
This study was presented in the 2nd Mekkah International
Conference in its early phases, and this article provides an up-
date and continuation of the same study in its period VI.
Limitations of the study included:
1. Inclusion of subgroup analysis for culture result.
2. Differences in indications and concomitant complications.
3. Resistance patterns of the different strains of the infective
organisms.
4. What is new and conclusion
This study showed improvement in antimicrobial use after the
intervention of the clinical pharmacist and ID. Involvement of
the clinical pharmacist and ID is highly recommended to opti-
mize the use of antimicrobials, and decrease antimicrobial
resistance in hospitalized patients. We recommend continua-
tion of the study to maintain supervision over quality, decrease
resistance (Regal et al., 2003), and monitor the need for inter-
vention in the different wards. Surveillance of consumption of
reserved antibiotics should be done according to local guide-
lines, as well as for external comparison. This can save medical
staff the burden of managing patients chronically, or having
deteriorating patients in the wards.References
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